4D Molecular Therapeutics, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 6.99M13.61M18.04M3.13M20.72M0.04M
Gross Profit 6.99M13.61M18.04M3.13M20.72M0.04M
Operating items
Research & Development 38.72M53.04M61.36M80.25M97.10M141.30M
Selling, General & Administrative 13.89M17.24M28.01M32.91M36.49M46.58M
Other Operating Expenses 5.14M
Operating Expenses 57.75M70.28M89.37M113.16M133.59M187.88M
Operating Income -50.76M-56.66M-71.33M-110.03M-112.87M-187.84M
EBIT -50.76M-56.66M-71.33M-110.03M-112.87M-187.84M
Non-operating items
Interest & Investment Income 1.50M0.15M0.14M2.57M12.21M27.05M
Other Non Operating Income -0.05M-0.18M-0.12M-0.04M-0.18M-0.08M
Non Operating Income 1.46M-0.18M-0.12M2.54M12.03M26.97M
Net income details
EBT -49.26M-56.51M-71.20M-107.46M-100.66M-160.79M
Profit After Tax -49.31M-56.69M-71.32M-107.49M-100.84M-160.87M
Income from Continuing Operations -49.26M-56.51M-71.20M-107.46M-100.66M-160.79M
Consolidated Net Income -49.26M-56.51M-71.20M-107.46M-100.66M-160.79M
Income towards Parent Company -49.26M-56.51M-71.20M-107.46M-100.66M-160.79M
Net Income towards Common Stockholders -49.31M-56.69M-71.32M-107.49M-100.84M-160.87M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 23.83M32.14M32.39M42.75M46.23M
Shares Outstanding (Diluted Average) 27.73M32.35M39.13M53.94M
EBITDA -50.76M-56.66M-71.33M-110.03M-112.87M-187.84M
Shares Outstanding 5.18M26.68M32.22M32.63M43.08M45.79M